Trial
NCT01668654
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
Bausch Health Americas, Inc.
Condition
Epilepsy
Intervention
retigabine/ezogabine
Why stopped
FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-30